Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Cancer Control : Journal of the Moffitt Cancer Center|May 27, 2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast CancerDionisia Quiroga, Robert Wesolowski, Sara Zelinskas, et al.
Frontiers in Oncology|March 20, 2026
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping reviewCaroline Lommer, Lila Schroeder, Caroline Amato, et al.
Plos One|March 12, 2010
A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic targetDaniel M Appledorn, Yasser A Aldhamen, William Depas, et al.
Frontiers in Oncology|April 10, 2026
Case Report: Late choroidal metastasis from hormone receptor-positive, HER2-negative breast cancer responsive to first-line endocrine therapyHisham Alsharif, Robert Wesolowski, Colleen M Cebulla, et al.
JACC. Case Reports|May 9, 2025
Pembrolizumab-Induced Smoldering Myocarditis in Patients With Triple-Negative Breast CancerAdnan Shaaban, Alma Habib, Dionisia Quiroga, et al.
Cancer Medicine|June 19, 2024
Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancerJasmine S Sukumar, Sagar Sardesai, Andy Ni, et al.
Cancer Control : Journal of the Moffitt Cancer Center|May 4, 2026
Denosumab as Second-Line Treatment in Patients With Metastatic Breast Cancer: A Retrospective Descriptive Pilot Study From a Single InstitutionBriana To, Laura E Wright, Dureti Doto, et al.
The Oncologist|July 16, 2026
Impact of Oncotype DX Risk Categorization and Receipt of Chemotherapy on Survival Outcomes Among Patients with Small Node-Negative HR+ Breast CancerAndrea House, Julie A Stephens, Robert Wesolowski, et al.
Breast Cancer Research and Treatment|December 16, 2025
Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancerEric Schupp, Yevgeniya Gokun, Jacob Eckstein, et al.
NPJ Breast Cancer|June 19, 2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancerKai C C Johnson, Ai Ni, Dionisia Quiroga, et al.
Pageof 5